Olanzapine in diverse syndromal and subsyndromal exacerbations of bipolar disorders

Janenawasin, Suttiporn; Wang, Po; Lembke, Anna; Schumacher, Matthew; Das, Bibi; Santosa, Claudia; Mongkolcheep, Jenny; Ketter, Terence A.

doi:10.1034/j.1399-5618.2002.01210.x

Cited by 10 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A 9-week open trial of olanzapine in 25 subjects with BDs presenting with depressed or elevated mood reported a 60% response rate (CGI £ 2) (36). Though results for the 10 BD II patients included in the study were not reported separately, the authors noted that a significant difference across bipolar subtypes was not found (36). One wonders whether the study was adequately powered to detect such a difference if it were in fact present.…”

Section: Antipsychoticsmentioning

confidence: 96%

“…T here has been a recent surge of interest in refining the definition of bipolar II disorder (BD II) (1)(2)(3)(4)(5)(6)(7)(8). Efforts to reconsider the conceptual contours of BD II, coupled with emerging data on its epidemiology (9)(10)(11)(12), natural history (13)(14)(15)(16)(17)(18), diagnosis (19)(20)(21)(22)(23)(24)(25)(26)(27), and management (28)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38), will likely have a considerable impact on clinical practice. We distill these developments in this paper.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Bipolar II Disorder: An Overview of Recent Developments

2004

View full text Add to dashboard Cite

show abstract

Section: Antipsychoticsmentioning

confidence: 96%

mentioning

confidence: 99%

Bipolar II Disorder: An Overview of Recent Developments

2004

View full text Add to dashboard Cite

show abstract

“…Olanzapine is associated with minimal QTc prolongation (1.7 ms) and is effective in treating mood and anxiety disorders. [30][31][32][33][34] This patient noted rapid resolution of his affective, obsessive, and anxiety symptoms on low dosage olanzapine.…”

Section: Discussionmentioning

confidence: 82%

Arsenic trioxide and olanzapine co-administration: case analysis

Kaufman

Chhabra

Levitt

et al. 2009

J Oncol Pharm Pract

View full text Add to dashboard Cite

QTc prolongation is associated with arsenic trioxide (ATO) treatment of acute promyelocytic leukemia (APL). Olanzapine was safely co-administered with ATO to treat co-morbid psychiatric diagnoses. It is important to closely monitor for drug-drug interactions and cumulative drug adverse effects in patients receiving oncology agents and psychotropics. Further research is indicated to determine risk/benefit profiles of psychotropics co-administered with ATO. In light of current limited data, co-administration of psychotropics with ATO should be reported presenting both instances wherein no interactions are noted and those with adverse effects.

show abstract

“…In another single arm open-label study by Janenawasin et al (2002), 70% of bipolar depressed patients were judged as moderately to markedly improved after 9 weeks of treatment with olanzapine alone (N ¼ 10) or olanzapine þ mood stabilizer (N ¼ 15). The study sample also consisted of patients with bipolar I or II disorder, and bipolar disorder NOS.…”

Section: Discussionmentioning

confidence: 99%

Olanzapine monotherapy for acute depression in patients with bipolar I or II disorder: results of an 8‐week open label trial

Bobo

Epstein

Shelton

2009

Human Psychopharmacology

View full text Add to dashboard Cite

We evaluated the efficacy, tolerability, and safety of olanzapine monotherapy in 20 adult patients with bipolar I or II disorder, depressed phase. Patients received open-label olanzapine monotherapy (mean modal dose, 15 mg/day) for 8 weeks. Assessments of psychopathology (Montgomery-Asberg Depression Rating Scale [MADRS], Quick Inventory of Depressive Symptomatology [QIDS-SR-16], Young Mania Rating Scale [YMRS]), clinical global state (Clinical Global Impressions [CGI] scale), and safety/tolerability were performed at baseline, and at 1, 2, 4, 6, and 8 weeks. Seventeen patients (85.0%) completed the study. Improvement in MADRS total scores was observed after the first week of treatment, and at all remaining follow-up time points (p < or = 0.005). Parallel improvement in QIDS-SR-16 (p < 0.001) and CGI-Severity (p < 0.001) was observed between baseline and study endpoint. Nine (45%) subjects achieved positive treatment response, eight of whom (40%) also achieved symptom remission. There were significant increases in weight (+3.2 kg, p = 0.001) and body mass index (+1.1 kg/m(2), p = 0.001), but not fasting glucose or lipids, with the exception of reduced triglyceride levels in the overall sample, and reduced HDL cholesterol in females. Olanzapine may be an effective, well-tolerated option for treating acute non-psychotic depression across a variety of bipolar disorder subtypes.

show abstract

Olanzapine in diverse syndromal and subsyndromal exacerbations of bipolar disorders

Cited by 10 publications

References 25 publications

Bipolar II Disorder: An Overview of Recent Developments

Bipolar II Disorder: An Overview of Recent Developments

Arsenic trioxide and olanzapine co-administration: case analysis

Olanzapine monotherapy for acute depression in patients with bipolar I or II disorder: results of an 8‐week open label trial

Contact Info

Product

Resources

About